The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics. In this video, recorded at the 2025 LUGPA Annual Meeting, Arpeet Shah, MD, a urologist ...
Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...
LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting. Stay current with the latest urology news and practice-changing insights — ...
This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these ...
Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC. A retrospective analysis of the COSMIC-313 trial (NCT03937219) suggests that KIM-1 is prognostic for clinical outcomes and may ...
212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...
177Lu-PSMA-617 addition to ADT and ARPI significantly improved rPFS in PSMA-positive mHSPC patients, with consistent benefits across subgroups. The PSMAddition trial showed a trend toward improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback